KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
Juan Esteban García-Robledo, Rafael Rosell, Alejandro Ruíz-Patiño, Carolina Sotelo, Óscar Arrieta, Lucía Zatarain-Barrón, Camila Ordóñez‐Reyes, Elvira Jaller, Leonardo Rojas, Alessandro Russo, Diego de Miguel‐Pérez, Christian Rolfo, Andrés F. Cardona
Abstract
Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor's molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.